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Abstract
 
Aims
 
Cholesteryl ester transfer protein (CETP) exchanges neutral lipids
between lipoproteins. As the role of CETP in the atherogenic process is still not
fully clarified, we studied the association of CETP concentration with the pre-
valence of cardiovascular disease (CVD) and with intima-media thickness of the
carotid artery (IMT) in subjects with normal glucose tolerance (NGT), impaird
fasting glucose and/or impaired glucose tolerance (IFG/IGT) and Type 2 diabetes
mellitus.
 
Methods
 
Subjects (
 
n
 
 = 566) were recruited from the 2000–2001 follow-up
examination of the Hoorn study. CETP concentration was determined by
immunoassay. CVD was defined as self-reported history of arterial surgery,
cerebral vascular event, amputation, angina, claudication, possible infarction,
measured ankle-brachial index < 0.90 or ECG abnormalities. The right com-
mon carotid artery IMT was measured by ultrasound at 10 mm proximal to the
carotid bulb.
 
Results
 
In men, CETP concentration was not associated with CVD, irre-
spective of glucose tolerance status. In women with NGT or IGT, there was also
no relationship. However, in women with Type 2 diabetes, the risk of CVD was
increased in those with high CETP concentration [odds ratio = 3.34 (1.56;
7.14)]. No statistically significant association was found between CETP con-
centration and IMT in the entire cohort.
 
Conclusions
 
In an elderly Caucasian population, associations of CETP con-
centration with CVD were dependent on glucose tolerance status and gender. The
finding that high CETP concentration was strongly associated with increased
prevalence of CVD in women with Type 2 diabetes warrants further investigation.
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Introduction
 
Disturbances in lipoprotein metabolism play a major role in
atherogenesis. Increased levels of low-density lipoprotein
(LDL) cholesterol (LDL-c) and triglycerides, associated with the
occurrence of small dense LDL, and decreased levels of HDL-
cholesterol (HDL-c) characterize dyslipidaemia. Cholesteryl
ester transfer protein (CETP) plays an important role in lipid
metabolism by mediating the transfer of esterified cholesterol
(CE) from high-density lipoprotein (HDL) to apolipoprotein
B-containing lipoproteins in exchange for triglycerides [1].
To date, it has been difficult to define the role of CETP in
atherogenesis. A high CETP activity decreases HDL-c levels
and lowering CETP activity by investigational drugs has been
shown to increase HDL-c concentration [2] and to decrease
LDL-c concentration [3]. In contrast, CETP plays an important
role in reverse cholesterol transport by promoting the trans-
port of CE to the liver by LDL or very low-density lipoprotein
(VLDL) [4]. In the presence of efficient hepatic uptake of the
latter lipoproteins or their contents, this may be favourable. It
is likely that the individual lipid profile determines the way in
which CETP affects atherogenesis [5]. In a number of previous
studies, high CETP concentration was associated with increased
risk of coronary artery disease in individuals with increased
triglyceride levels [6], familial hypercholesterolaemia [7], men
with established coronary artery disease [8] and in Type 2
diabetic patients [9]. One study showed that the association
between CETP and coronary artery disease was explained by
decreased HDL-c levels [6], while other studies did not [7–9].
Disturbances in lipid metabolism and high risk of athero-
sclerosis and cardiovascular disease (CVD) are common features
of diabetes. Little is known about the association between CETP
concentration and CVD in these patients. Therefore, we studied
the associations of CETP concentration with CVD and intima-
media thickness (IMT) of the carotid artery in subjects with normal
glucose tolerance (NGT), impaired fasting glucose and/or impaired
glucose tolerance (IFG/IGT) and Type 2 diabetes mellitus.
In addition, we investigated the association of the 
 
−
 
629C/A
polymorphism in the promotor region of the CETP gene with
CVD and IMT.
 
Subjects and methods
 
Study population
 
The Hoorn Study is a population-based cohort study of Type 2
diabetes in the general Dutch population. The population and
the study design have been described in detail previously [10].
Briefly, in 1989, 3553 men and women, aged 50–74 years, were
randomly selected from the population register of the medium-
sized Dutch town of Hoorn; 2484 Caucasian subjects agreed to
participate. In the 2000–2001 Hoorn Study follow-up exam-
ination, 1074 individuals of the original Hoorn Study cohort
were re-invited. We invited all surviving subjects with Type 2
diabetes (
 
n
 
 = 176), and random samples of individuals with
normal glucose tolerance (
 
n
 
 = 705) or impaired glucose tolerance
(
 
n
 
 = 193) based on their glucose tolerance status at the previous
examination (WHO-99 criteria) [11]. Of these 1074 subjects,
648 (60.3%) subjects participated in the follow-up examination.
To increase the number of diabetic individuals, we additionally
invited 217 participants from the Hoorn Screening Study
[12], of whom 188 agreed to participate. Among the 455 non-
participants, 13% were complete non-responders. Other reasons
not to participate were lack of interest (30%), co-morbidity
(23%), age (7%), unwillingness to travel (6%), participation
too time-consuming (6%), and miscellaneous reasons (15%)
[13]. Finally, 836 subjects participated in the study. The study
was approved by the ethics committee of the VU University
Medical Center. All subjects gave written informed consent.
From the participating 836 subjects, we excluded subjects
with missing data on primary variables of interest [glucose
tolerance status (
 
n
 
 = 24), CETP concentration (
 
n
 
 = 52), ultra-
sound examination of the carotid artery (
 
n
 
 = 76) mainly be-
cause of unsatisfactory definition of the arterial wall because of
obesity [13]]. Subjects who used medication which is known to
affect lipid metabolism (
 
n
 
 = 118) and CETP concentration [14]
were also excluded. The resulting complete dataset for primary
values of interest contained of 566 subjects (231 with NGT,
127 with IFG/IGT and 208 with Type 2 diabetes). Glucose
tolerance status was defined again at the follow-up examination
according to the WHO-99 criteria [11].
 
Anthropometric measurements and questionnaires
 
Anthropometric measurements were obtained from all par-
ticipants. Weight and height were measured in barefooted
participants wearing light clothes only. Body mass index (BMI)
was calculated as weight (kg) divided by the square of height
(m). Information about alcohol intake was obtained from a
validated food-frequency questionnaire [15].
 
Laboratory analyses
 
Fasting and 2-h post-load plasma glucose concentrations
were determined by the glucose dehydrogenase method and
triglycerides, total cholesterol and HDL-c were determined by
enzymatic techniques (Roche, Mannheim, Germany).
LDL-c was directly determined by the N-geneous
 
™
 
 assay
(Genzyme, Cambridge, MA, USA). LDL size was measured by
high-performance gel-filtration chromatography as previously
described in detail [16,17].
CETP concentration was measured by a two-antibody
sandwich immunoassay, which was developed and described
by Niemeijer-Kanters 
 
et al
 
. [18]. Inter-assay and intra-assay
coefficients of variation were 7.8 and 6.0%, respectively. As a
standard, pool plasma containing 2 mg CETP/mL was taken.
DNA was extracted from white blood cells for genotyping. We
used the polymerase chain reaction method as described by
Klerkx and co-workers to assess the presence of the C
 
→
 
A
variance in the promoter region of the CETP gene [19].
 
Cardiovascular disease
 
Resting 12-lead ECGs were recorded and automatically coded
according to the Minnesota code [20] with an automated
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diagnostic classification system (Modular ECG Analysis System)
[21]. An ECG was considered abnormal with Minnesota codes
1–1, 1–2, 1–3, 4–1, 4–2, 4–3, 5–1, 5–2, 5–3 or 7–1.
Doppler-assisted systolic blood pressure measurements were
performed in duplicate, from brachial, posterior tibial and
dorsalis pedis arteries on both the left and the right side. Ankle-
brachial index was calculated for each leg by the highest of the
posterior tibial and the dorsalis pedis average pressure divided
by the brachial pressure on the same side.
The Rose questionnaire [22] was used to determine presence
of angina, claudication or possible myocardial infarction.
CVD was defined as self-reported history of arterial surgery,
cerebrovascular event, amputation, angina, claudication or
possible infarction or measured ankle-brachial index < 0.90 or
ECG abnormalities.
 
Ultrasound imaging
 
Procedures and reproducibility of scanning are described in
detail elsewhere [13]. In summary, an ultrasound scanner (350
Series; Pie Medical, Maastricht, the Netherlands), equipped
with a 7.5-MHz linear probe, was operated by a single observer.
Three measurements, 4 s each, were performed in the right
common carotid artery at 10 mm proximal to the carotid bulb.
Images were registered and analysed by a computer equipped
with vessel wall movement detection software and an acquisition
system (Wall Track System; Pie Medical).
 
Statistical analyses
 
All analyses were performed in SPSS version 10.1 (SAS Institute,
Cary, NC, USA). Characteristics of the study population were
divided according to categories of glucose tolerance status
and gender. Data are presented as means (
 
SD
 
) or for skewed
data, as medians (interquartile range). Differences in baseline
measurements between categories of glucose tolerance status
and gender were examined using 
 
ANOVA
 
 for continuous data
and Kruskal–Wallis analysis for dichotomous data. All 
 
ANOVA
 
analyses were adjusted for age. Deviation from the Hardy–
Weinberg equilibrium for frequencies of the 
 
−
 
629C/A polymor-
phism was tested by chi-square.
Logistic regression was used to examine the association of
CETP concentration with CVD. Age-adjusted odds ratios (OR)
with 95% CI were obtained from logistic regression analysis.
Linear regression analysis was used to examine the association
of CETP concentration with IMT; results were reported as
betas (95% CI). A beta of 10 would indicate that, if CETP con-
centration increases 1 mg/l, IMT increases by 10 
 
µ
 
m. We tested
for possible interactions of CETP concentration with glucose
tolerance status, gender, smoking, triglycerides and study
population (original Hoorn Study cohort or Hoorn Screening
Study) by calculating the 
 
P
 
 values of the interaction terms.
Subsequently, we adjusted for HDL-c and triglycerides, which
were considered as possible confounding factors. Finally, BMI,
total cholesterol, systolic blood pressure, alcohol intake, smok-
ing, LDL-c, LDL size, waist circumference and fasting insulin
were considered as possible confounding factors and were
added to a multivariate model. The final multivariate model
included the factors that altered the estimated beta for prevalent
CVD or IMT. For interaction, a 
 
P
 
 value < 0.10 was considered
statistically significant, whereas we used 
 
P
 
 < 0.05 as statistically
significant for all other analyses.
 
Results
 
Characteristics of the study population
 
Results were reported in groups of glucose tolerance status and
for men and women separately because of observed inter-
actions between CETP concentration and gender and between
CETP concentration and glucose tolerance status with regard
to CVD. Table 1 shows the characteristics of the study popu-
lation stratified for categories of glucose tolerance status and
gender. CETP concentration was higher in women than in men
(
 
P <
 
 0.01, all men compared with all women), but did not
differ significantly between categories of glucose tolerance.
IMT was higher and CVD was commoner in subjects with IFG/
IGT and diabetes in both sexes, although this increase only
reached statistical significance in women (
 
P <
 
 0.01 and 
 
P
 
 = 0.01
for IMT and for CVD, respectively). The total prevalence of
CVD was 48.9%. In the majority of these subjects, CVD was
defined as ECG abnormalities, ankle-brachial index < 0.90,
amputation or arterial surgery. The prevalence of self-reported
CVD based on the Rose questionnaire only (angina, claudica-
tion and possible myocardial infarction) was 3% in the entire
study population.
 
Associations of CETP concentration with CVD and IMT
 
In men, CETP concentration was not associated with the
prevalence of CVD, independent of glucose tolerance status.
In women with NGT or IFG/IGT, we also noted the absence
of such a relation. However, in women with Type 2 diabetes,
CETP concentration was strongly associated with CVD risk
[OR = 3.34 (1.56; 7.14); 
 
P
 
 value for interaction between
diabetes and CETP concentration: 
 
P
 
 < 0.01]. Importantly, this
association was not attenuated after adjustments for HDL-c,
triglycerides or other CVD risk factors (Table 2). Also, alcohol
intake, LDL-c, LDL-size, waist circumference and fasting
insulin did not alter the estimate (data not shown). In women
with NGT, the weak inverse association between high CETP
concentration and CVD was not statistically significant.
No association was found between CETP concentration and
IMT in men with NGT, IFG/IGT or diabetes, nor was there an
association in women with IFG/IGT or diabetes. The relation-
ship between CETP concentration and IMT in women with NGT
did not reach statistical significance (
 
P =
 
 0.054, Table 3).
Because no statistically significant interaction with glucose
tolerance status or gender was found with regard to IMT, a
regression coefficient for CETP in the combined study popu-
lation is considered more appropriate. CETP was not statisti-
cally significantly associated with IMT in the total study
population [beta = 15.0 (
 
−
 
6.6; 36.7)], adjusted for age, gender
and glucose tolerance status).
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No statistical significant interactions were found between
CETP concentration and smoking, triglycerides or study
population with regard to either prevalence of CVD or
IMT.
 
629C/A polymorphism
 
Frequencies of the 
 
−
 
629C/A polymorphism were equally
distributed over categories of glucose tolerance status. The
number of A alleles of the 
 
−
 
629C/A polymorphism was
associated with lower CETP concentration (
 
P <
 
 0.01) and with
higher HDL-c levels (
 
P =
 
 0.01). The 
 
−
 
629C/A polymorphism
was not associated with CVD or IMT (data not shown).
 
Discussion
 
This population-based study showed a strong and independent
association between fasting CETP concentration and the
prevalence of CVD in women with Type 2 diabetes, while no
clear associations with IMT were observed.
This is in line with the hypothesis that CETP should be more
detrimental in patients with diabetes than in subjects with
NGT [23]. Subjects with diabetes or IGT have, in addition to
glucose abnormalities, elevated concentrations of triglycerides
and cholesterol and decreased HDL-c levels [24]. In patients
with high triglyceride levels, CETP preferentially directs
CE from HDL to larger VLDL [25]. In this CETP-mediated
Table 1 Characteristics of the study population stratified for glucose tolerance status and gender (n = 566)
Men Women
NGT IFG/IGT Type 2 diabetes NGT IFG/IGT Type 2 diabetes
n 109 64 104 122  63 104
Age (years) 69.3 (6.3) 68.3 (6.2) 67.2 (8.4) 68.2 (6.1) 70.9 (5.7) 69.7 (7.5)
Fasting glucose (mmol/l) 5.5 (0.4) 6.1 (0.5) 7.7 (1.9) 5.4 (0.4) 6.0 (0.5) 7.6 (1.8)
Two-hour post-load glucose (mmol/l) 5.4 (1.1) 7.7 (1.8) 11.2 (2.6) 5.7 (1.1) 8.0 (1.5) 12.1 (2.9)
Triglycerides (mmol/l) 1.3 (0.9–1.5) 1.3 (1.0–1.8) 1.5 (1.1–2.0) 1.1 (0.8–1.5) 1.3 (0.9-1.8) 1.6 (1.1–2.0)
HDL cholesterol (mmol/l) 1.33 (0.37) 1.29 (0.34) 1.14 (0.30) 1.70 (0.41) 1.63 (0.45) 1.39 (0.34)
LDL cholesterol (mmol/l) 3.6 (0.9) 3.8 (0.9) 3.4 (0.8) 3.9 (0.9) 4.0 (1.0) 3.7 (0.9)
LDL size (nm) 21.51 (0.34) 21.44 (0.38) 21.20 (0.44) 21.80 (0.32) 21.58 (0.44) 21.44 (0.48)
Total cholesterol (mmol/l) 5.5 (0.9) 5.7 (1.0) 5.3 (0.9) 6.2 (0.9) 6.3 (1.0) 6.0 (1.0)
BMI (kg/m2) 25.8 (3.1) 26.7 (2.9) 28.6 (3.4) 26.0 (3.0) 27.9 (4.6) 28.5 (4.1)
Waist (cm) 95.2 (9.5) 98.8 (9.4) 103.5 (10.3) 85.7 (9.3) 93.1 (10.9) 95.5 (10.9)
Systolic blood pressure (mmHg) 140 (18) 140 (16) 145 (20) 137 (22) 144 (19) 147 (21)
Diastolic blood pressure (mmHg) 83 (10) 84 (11) 85 (10) 81 (12) 81 (10) 84 (10)
Current smoker (%) 18.3 21.9 13.5 13.1 11.1 11.7
Alcohol intake (g/day) 11.1 (2.4–27.4) 13.3 (4.1–33.1) 9.4 (2.6–26.9) 4.4 (0.7–12.1) 2.9 (0.4–11.8) 0.4 (0–5.9)
CETP (mg/l) 1.75 (0.52) 1.88 (0.61) 1.70 (0.59) 2.07 (0.58) 2.14 (0.56) 2.02 (0.68)
−629 CC/CA/AA (%) 34/43/22 26/40/33 26/47/27 28/51/21 27/41/32 28/51/21
Carotid IMT (µm) 854 (180) 877 (183) 880 (196) 798 (144) 854 (132) 885 (156)
Cardiovascular disease (%)* 44.9 47.6 52.6 41.8 45.9 61.0
*Cardiovascular disease defined as ankle-brachial index < 0.90, ECG abnormalities, history of arterial surgery, cerebral vascular event, angina, 
amputation, claudication or possible myocardial infarction.
Table 2 Associations [OR (95% CI)] of CETP with CVD stratified for glucose tolerance status and gender
Men Women
NGT IFG/IGT Type 2 diabetes NGT IFG/IGT Type 2 diabetes
Age-adjusted* 1.22 (0.54;2.78) 1.51 (0.60;3.80) 1.26 (0.62;2.57) 0.66 (0.35;1.26) 1.24 (0.49;3.16) 3.34 (1.56;7.14)
Age and HDL-c adjusted 1.22 (0.53;2.78) 1.61 (0.63;4.12) 1.55 (0.70;3.45) 0.67 (0.35;1.29) 1.21 (0.46;3.20) 3.37 (1.57;7.24)
Age and triglycerides adjusted 1.18 (0.51;2.72) 1.51 (0.59;3.88) 1.10 (0.51;2.39) 0.66 (0.34;1.26) 1.20 (0.47;3.07) 3.33 (1.54;7.22)
Multiple adjusted† 1.10 (0.44;2.74) 1.21 (0.44;3.34) 1.58 (0.69;3.62) 0.50 (0.25;1.01) 1.41 (0.53;3.72) 3.25 (1.44;7.35)
*OR per 1 mg/l increase in CETP concentration.
†Adjusted for age, BMI, total cholesterol, systolic blood pressure and smoking.
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transport, C
E
 is exchanged for triglycerides, w
hich are directed
to L
D
L
 and H
D
L
. T
hese L
D
L
 and H
D
L
 particles becom
e
triglyceride enriched, providing a substrate for hepatic lipase
to generate sm
all dense L
D
L
 and H
D
L
, w
hich are considered
to be atherogenic [4]. In addition, C
E
T
P contributes to the
atherogenity of sm
all dense L
D
L
 in an indirect w
ay by enrich-
m
ent of V
L
D
L
 particles w
ith C
E
. T
hese large, C
E
-enriched
V
L
D
L
 particles are a precursor of sm
all dense L
D
L
 [23].
T
herefore, high levels of C
E
T
P concentration are expected to
be atherogenic, particularly in subjects w
ith a large pool of
triglyceride-enriched lipoproteins, i.e. V
L
D
L
.
H
ow
ever, despite the association w
ith C
V
D
 in w
om
en w
ith
T
ype 2 diabetes, w
e did not observe an association betw
een
C
E
T
P concentration and IM
T
. T
his m
ay be related to a
num
ber of lim
itations of our study. A
lthough several studies
reported a high correlation betw
een C
E
T
P concentration and
C
E
T
P activity [26–28], the w
eak associations betw
een C
E
T
P
concentration and IM
T
 could be the result of m
easuring C
E
T
P
concentration instead of C
E
T
P activity. T
he relation betw
een
C
E
T
P activity and C
E
T
P concentration could differ in diabetic
individuals com
pared w
ith non-diabetic subjects [29]. Indeed,
a recent study show
ed an association betw
een C
E
T
P activity
and IM
T
, w
hile no association w
as found betw
een C
E
T
P
concentration and IM
T
 [29]. Furtherm
ore, m
easuring fasting
C
E
T
P concentration m
ay be less relevant than m
easuring
postprandial C
E
T
P concentration to the risk of atherosclerosis
and C
V
D
, especially in diabetes. Postprandial changes in C
E
T
P
concentration and activity w
ere found in tw
o studies [30,31],
although not in one sm
all study [32].
U
ntil 
now
, 
no 
other 
studies 
exam
ined 
the 
association
betw
een C
E
T
P concentration and C
V
D
 in different categories
of glucose tolerance. T
he finding that C
E
T
P concentration and
C
V
D
 are not related to each other in non-diabetic subjects is in
line w
ith previous studies [6–9]. T
he beneficial effects of C
E
T
P
in reverse cholesterol transport m
ight be dom
inant in healthy
subjects w
ho have efficient hepatic uptake of cholesterol.
A
 
gender 
difference 
regarding 
the 
association 
betw
een
C
E
T
P and C
V
D
 has not been observed previously. T
he associ-
ation betw
een C
E
T
P concentration and C
V
D
 in w
om
en w
ith
T
ype 2 diabetes w
as, how
ever, very strong and of sim
ilar
m
agnitude in w
om
en from
 the H
oorn Screening Study an
d
in w
om
en from
 the original H
oorn Study cohort. It has been
previously show
n that, in w
om
en, the relative risk of C
V
D
conferred by diabetes is greater than in m
en [33]. In view
 of the
gender difference in the association betw
een C
E
T
P and C
V
D
in the current study, C
E
T
P m
ight be a m
ediator of C
V
D
 risk.
In line w
ith previous findings, the w
om
en studied here had
significantly higher levels of C
E
T
P than m
en, w
hich m
ight
reflect a higher neutral lipid exchange rate betw
een lipoproteins.
In the presence of a high concentration of V
L
D
L
 particles, as
in diabetes [34], a high C
E
T
P concentration m
ay contribute to
the high risk of C
V
D
 in diabetic w
om
en [35]. A
n additional
possible explanation of the lack of association in m
en m
ay be
selective survival. In this study population, w
om
en w
ith
diabetes w
ere older than m
en (m
en aged 67.2 years and w
om
en
Table 3 Associations [β (95% CI)] of CETP with carotid IMT stratified for glucose tolerance status and gender
Men Women
NGT IFG/IGT Type 2 diabetes NGT IFG/IGT Type 2 diabetes
Age adjusted* 2.3 (−59.7;64.3) 27.6 (−41.4;96.7) 4.0 (−55.7;63.7) 40.0 (−0.6;80.5) 21.5 (−30.6;73.6) −10.1 (−54.4;34.2)
Age and HDL-c adjusted 1.9 (−60.4;64.2) 31.1 (−38.1;100.2) 7.6 (−52.4;67.7) 39.8 (−1.1;80.7) 14.8 (−40.0;69.6) −12.2 (−56.8;32.3)
Age and triglycerides adjusted 6.1 (−56.2;68.4) 39.3 (−30.7;109.2)  0 (−61.4;61.3) 39.0 (−1.7;79.7) 17.5 (−34.2;69.2) −9.5 (−54.0;35.1)
Multiple adjusted† −7.6 (−73.5;58.3) 16.9 (−56.2;89.9) 13.5 (−52.8;79.9) 39.4 (−2.2;81.0) 18.0 (−35.3;71.3) −30.2 (−77.5;17.1)
*Beta in µm IMT per 1 mg/l increase in CETP concentration.
†Adjusted for age, BMI, total cholesterol, systolic blood pressure and smoking.
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aged 69.7 years). Thus, in men who had an atherogenic lipid
profile, high CETP concentration and CVD may already have
deceased, in contrast to the surviving women.
We also found that the AA genotype was associated with an
anti-atherogenic lipid profile. As expected, the AA genotype
of the –629 C
 
→
 
A polymorphism was associated with lower
CETP concentration and with higher HDL-c levels [19], which
is generally regarded as an anti-atherogenic lipid profile. Other
studies have shown these differential effects on atherosclerosis
and CVD [36,37]. However, we found no associations between
the CETP gene and CVD or IMT. The lack of association in the
present study may be as a result of low statistical power. Indeed,
in a recent meta-analysis [38], the TaqIB polymorphism of the
CETP gene (acknowledged to be a marker for the functional
 
−
 
629C/A polymorphism) was associated with cardiovascular
events, whereas no association was found in most of the
individual studies included in the meta-analysis.
The current cross-sectional study design limits interpreta-
tion of our results. Patients who have had diabetes for several
years receive blood glucose-lowering therapy and often
change their lifestyle. As a consequence of these interventions,
regression of IMT [39] and changes in CETP concentration
may occur, while history of CVD remains unchanged. This
could explain the discrepancies observed in the association of
CETP with IMT and with CVD in the diabetic patients. In
addition, exclusion of subjects who used lipid-lowering
medication possibly resulted in a study population with a
relatively low cardiovascular risk profile. This may have led to
an underestimation of the true association between CETP
concentration and CVD and/or IMT. Because of limited
statistical power, we used a broad definition of CVD com-
pared with other studies [6]. Further study into more specific
CETP-related cardiovascular abnormalities might be help-
ful to elucidate a possible mechanistic pathway between
CETP and CVD. Furthermore, the current data warrant further
investigation into the value of CETP concentration in larger
prospective studies, which are unfortunately very limited thus
far [6–8].
In summary, associations of CETP concentration with
atherosclerosis and CVD were dependent on glucose tolerance
status and gender. The finding that high CETP concentration
was strongly associated with prevalent CVD in women with
Type 2 diabetes suggests that further investigation into CETP
as a possible mediator for CVD risk in patients with diabetes
is required.
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